Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 189-195, 2005. First published November 11, 2004; 10.1373/clinchem.2004.039735
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.039735v1
51/1/189    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schoonenboom, N. S.M.
Right arrow Articles by Blankenstein, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schoonenboom, N. S.M.
Right arrow Articles by Blankenstein, M. A.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:189-195.)
© 2005 American Association for Clinical Chemistry, Inc.

General Clinical Chemistry

Effects of Processing and Storage Conditions on Amyloid ß (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice

Niki S.M. Schoonenboom1,2,2,a, Cees Mulder2,2, Hugo Vanderstichele3, Evert-Jan Van Elk2, Astrid Kok2, Gerard J. Van Kamp2, Philip Scheltens1 and Marinus A. Blankenstein2

1 Alzheimer Center and Department of Neurology, and 2 Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
3 Innogenetics NV, Ghent, Belgium.

aAddress correspondence to this author at: Departments of Neurology and Clinical Chemistry, VU University Medical Center, Postbus 7057, 1081 HV Amsterdam, The Netherlands. Fax 31-204440715; e-mail niki.schoonenboom{at}vumc.nl

Background: Reported concentrations of amyloid ß (1–42) (Aß42) and tau in cerebrospinal fluid (CSF) differ among reports. We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of Aß42 and tau in CSF.

Methods: Stability of samples stored at –80 °C was determined by use of an accelerated stability testing protocol according to the Arrhenius equation. Aß42 and tau concentrations were measured in CSF samples stored at 4, 18, 37, and –80 °C. Relative CSF concentrations (%) of the biomarkers after one freeze/thaw cycle were compared with those after two, three, four, five, and six freeze/thaw cycles. In addition, relative Aß42 and tau concentrations in samples not centrifuged were compared with samples centrifuged after 1, 4, 48, and 72 h.

Results: Aß42 and tau concentrations were stable in CSF when stored for a long period at –80 °C. CSF Aß42 decreased by 20% during the first 2 days at 4, 18, and 37 °C compared with –80 °C. CSF tau decreased after storage for 12 days at 37 °C. After three freeze/thaw cycles, CSF Aß42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. Centrifugation did not influence the biomarker concentrations.

Conclusions: Repeated freeze/thaw cycles and storage at 4, 18, and 37 °C influence the quantitative result of the Aß42 test. Preferably, samples should be stored at –80 °C immediately after collection.




The following articles in journals at HighWire Press have cited this article:


Home page
 NeurologyHome page
F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom, E. J. van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, and P. Scheltens
Longitudinal changes of CSF biomarkers in memory clinic patients
Neurology, September 4, 2007; 69(10): 1006 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
D. de Jong, R. W. M. M. Jansen, B. P. H. Kremer, and M. M. Verbeek
POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 924 - 925.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. H. Bouwman, W. M. van der Flier, N. S.M. Schoonenboom, E. J. van Elk, A. Kok, P. Scheltens, and M. A. Blankenstein
Usefulness of Longitudinal Measurements of {beta}-Amyloid1-42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders.
Clin. Chem., August 1, 2006; 52(8): 1604 - 1606.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Lewczuk, G. Beck, H. Esselmann, R. Bruckmoser, R. Zimmermann, M. Fiszer, M. Bibl, J. M. Maler, J. Kornhuber, and J. Wiltfang
Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid {beta} Peptides
Clin. Chem., February 1, 2006; 52(2): 332 - 334.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby
Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry
Clin. Chem., September 1, 2005; 51(9): 1637 - 1649.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. S.M. Schoonenboom, C. Mulder, H. Vanderstichele, Y. A.L. Pijnenburg, G. J. Van Kamp, P. Scheltens, P. D. Mehta, and M. A. Blankenstein
Differences and Similarities between Two Frequently Used Assays for Amyloid {beta} 42 in Cerebrospinal Fluid
Clin. Chem., June 1, 2005; 51(6): 1057 - 1060.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.